V018-4293 Screening compound: N-[(4-fluorophenyl)methyl]-2-(N-methyl-1-{5-[(3-methylphenyl)methyl]-4-oxo-4H,5H,6H,7H,8H-pyrazolo[1,5-a][1,4]diazepin-2-yl}formamido)acetamide

V018-4293 Screening compound: N-[(4-fluorophenyl)methyl]-2-(N-methyl-1-{5-[(3-methylphenyl)methyl]-4-oxo-4H,5H,6H,7H,8H-pyrazolo[1,5-a][1,4]diazepin-2-yl}formamido)acetamide
V018-4293 Screening compound: N-[(4-fluorophenyl)methyl]-2-(N-methyl-1-{5-[(3-methylphenyl)methyl]-4-oxo-4H,5H,6H,7H,8H-pyrazolo[1,5-a][1,4]diazepin-2-yl}formamido)acetamide alternative view

Chemical Structure Depiction of ChemDiv screening compound V018-4293
N-[(4-fluorophenyl)methyl]-2-(N-methyl-1-{5-[(3-methylphenyl)methyl]-4-oxo-4H,5H,6H,7H,8H-pyrazolo[1,5-a][1,4]diazepin-2-yl}formamido)acetamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

V018-4293

Molecular Formula

C26H28FN5O3 (C26 H28 FN5 O3)

Compound Name

N-[(4-fluorophenyl)methyl]-2-(N-methyl-1-{5-[(3-methylphenyl)methyl]-4-oxo-4H,5H,6H,7H,8H-pyrazolo[1,5-a][1,4]diazepin-2-yl}formamido)acetamide

IUPAC name

N-[(4-fluorophenyl)methyl]-2-(N-methyl-1-{5-[(3-methylphenyl)methyl]-4-oxo-4H5H6H7H8H-pyrazolo[15-a][14]diazepin-2-yl}formamido)acetamide

SMILES

Cc1cccc(CN(CCCn(c2c3)nc3C(N(C)CC(NCc(cc3)ccc3F)=O)=O)C2=O)c1

InChI

InChI=1S/C26H28FN5O3/c1-18-5-3-6-20(13-18)16-31-11-4-12-32-23(26(31)35)14-22(29-32)25(34)30(2)17-24(33)28-15-19-7-9-21(27)10-8-19/h3,5-10,13-14H,4,11-12,15-17H2,1-2H3,(H,28,33)

InChI Key

GROISBWRJAQUMP-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD19907590

Chemical and Physical Properties

Saltdata

not_available

Molecular Weight

477.54

Hydrogen Bond Acceptors Count

7.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

9.00

Number of Nitrogen and Oxygen Atoms

8

Partition Coefficient, logP

2.403

Distribution Coefficient, logD

2.403

Water Solubility, LogSw

-2.73

Polar Surface Area

71.004

Acid Dissociation Constant (pKa)

12.82

Base Dissociation Constant (pKb)

-1.29

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

30.80

V018-4293 in Drug Discovery

Included in Screening Libraries

GPCR Targeted Library (31838 compounds)

Macl-GPIb alpha Interaction Library (22969 compounds)

PPI Helix Turn 3D-Mimetics Library (71298 compounds)

Protein-Protein Interaction Library (218420 compounds)

SH2 Library (10483 compounds)

Alpha-Helix Mimetics Library (25899 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Musculoskeletal
  • Respiratory tract
  • Nervous system
  • Congenital
  • Skin
  • Metabolic
  • Endocrine
  • Hemic and lymphatic
  • Cardiovascular
  • Cancer
  • Endocrine
Targets:
  • GPCR
Mechanism of action:
  • Receptor's ligands
  • PPI modulators
  • PPI modulators
  • PPI modulators
  • PPI modulators
Structure:
  • Mimetics
  • Mimetics

References: we are preparing a list of scientific research reports with V018-4293 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound V018-4293?
Check Price and Availability of V018-4293, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of V018-4293 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for V018-4293
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for V018-4293
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of V018-4293 available by request